HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CBD Oral Sprays For Pain, Sleep, Weight Recalled On Microbial Contamination

Executive Summary

First report of salmonella contamination for a kratom supplement in nearly nine months prompts Sunstone Organics to recall one lot each of its white vein and maeng da types of the herb. FDA's latest recall database update includes Nutrafuels' recall of more than 1,500 of its CTFO Oral Spray with pure CBD hemp oil isolate dietary supplements for sleep support, weight loss and pain relief after third-party testing showed microbial contamination.

You may also be interested in...



FDA Warnings: Mariposa Done With OTCs, Thibiant's Long Correction List

GMP violations FDA inspectors found at Mariposa Labs' plant were repeats of a previous inspection. Thibiant International's problems included was "knowing the formulation was flawed" but making "a second batch using the same formulation."

Kratom Industry Group Has First Qualifier For Its GMP Standards Exceeding FDA's

Online retailer and supplement brand Kraken Kratom is first business American Kratom Association recognized with its GMP Qualified Vendor status. But, FDA reiterates kratom should not be used in supplements until an NDI notification is submitted showing a reasonable expectation of safety for its intended use, and DEA still has pending a proposed order to schedule kratom constituent ingredients as controlled substances.

House Appropriators Stoke Flames For FDA Regulation On CBD In Supplements

House Appropriations subcommittee with FDA oversight makes clear in questions for Commissioner Gottlieb they support allowing use of constituent ingredients from hemp and cannabis plants in food and dietary supplement products. Members also press for approving US firms' applications for pharmaceuticals with cannabis-derived active ingredients. Gottlieb announces working group will guide FDA decisions on potential CBD-use rulemaking.

Related Content

Topics

UsernamePublicRestriction

Register

MT142464

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel